TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26497307

Group type: EXPERIMENTAL
Intervention: Informative patient website, patient leaflet, follow-up consultation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Team training, checklists/flowcharts
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lack of information given by professionals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lack of clarity of the guidelines, lack of knowledge, failing team-communication
Number of subjects: 12
Study: 26497345

Group type: EXPERIMENTAL
Intervention: Open simple prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic simple prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic simple prostatectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral approaches with photon-based energy sources (i.e. laser prostatectomy)
Number of subjects: 0
Study: 26497660

Group type: EXPERIMENTAL
Intervention: SNPs rs6599230 and rs6843082
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SNPs rs1448817 and rs7193343
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SNPs rs1448817, rs17042171, rs3807989, and rs6843082
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SNPs rs17375901 and rs7193343
Number of subjects: 400
Study: 26497750

Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) infection
Number of subjects: 487247

Group type: EXPERIMENTAL
Intervention: Respiratory Syncytial Virus (RSV) infection in persons aged 65+ years
Number of subjects: 487247

Group type: EXPERIMENTAL
Intervention: High-risk elderly
Number of subjects: 487247

Group type: COMPARATOR
Intervention: RSV compared to influenza
Number of subjects: 487247
Study: 26497813

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 29
Study: 26498178

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: PCOS group with pregnancy complications
Number of subjects: 73

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 73
Study: 26498869

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 102
Study: 26499223

Group type: EXPERIMENTAL
Intervention: Parachute device
Number of subjects: 100
Study: 26499500

Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance (IMR)
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: Determinants of high IMR
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: Determinants of FFR ≤0.80
Number of subjects: 1096
Study: 26499927

Group type: EXPERIMENTAL
Intervention: Plasma levels of galectin-9 above 690 pg/mL
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Plasma levels of galectin-9
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Combination of galectin-9 level and Model For End-Stage Liver Disease score
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: One-time measurement of plasma galectin-9 level
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Competing risk analyses of galectin-9 levels
Number of subjects: 149
Study: 26500330

Group type: EXPERIMENTAL
Intervention: Patients with DM and mild/no DPN
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patients with DM and severe DPN
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patients with DM (both mild/no DPN and severe DPN)
Number of subjects: 34
Study: 26500339

Group type: EXPERIMENTAL
Intervention: Sequential scheme (9 cycles of VMP followed by 9 cycles of Rd; n = 118)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Alternating scheme (1 cycle of VMP followed by 1 cycle of Rd, up to 18 cycles; n = 115)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Sequential scheme
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Alternating scheme
Number of subjects: 233
Study: 26500686

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 44
Study: 26500687

Group type: EXPERIMENTAL
Intervention: Very low energy diet for 8 weeks
Number of subjects: 48
Study: 26501540

Group type: EXPERIMENTAL
Intervention: Red Blood Cell Concentrate Storage
Number of subjects: 0
Study: 26501758

Group type: EXPERIMENTAL
Intervention: Somatic dysfunction assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Somatic dysfunction severity score (SDSS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison of initial newborn assessment and research examination
Number of subjects: 100
Study: 26502812

Group type: EXPERIMENTAL
Intervention: Aβ1-42
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Aβ1-40
Number of subjects: 403
Study: 26502894

Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing (NGS) assay
Number of subjects: 101
Study: 26503201

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) doses of greater than 80.5 Gy (median, 58.05 Gy)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Radiotherapy (RT) doses of lower than 80.5 Gy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) doses of greater than 80.5 Gy
Number of subjects: 79
Study: 26503453

Group type: EXPERIMENTAL
Intervention: Discharge communication content as defined by physicians (34 items selected from 81)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Mnemonic acronym 'InFARcT' for structuring discharge information
Number of subjects: 51
Study: 26503811

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Summer daylight exposure (SDE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene expression networks
Number of subjects: 0
Study: 26504108

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 373

Group type: COMPARATOR
Intervention: Cryoballoon (CB) ablation
Number of subjects: 373
Study: 26504182

Group type: EXPERIMENTAL
Intervention: Sirolimus as monotherapy
Number of subjects: 30
Study: 26504524

Group type: EXPERIMENTAL
Intervention: Krill oil supplementation for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Olive oil supplementation for 4 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Krill oil supplementation for an additional 17 weeks
Number of subjects: 47
Study: 26506129

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26506270

Group type: EXPERIMENTAL
Intervention: ENROUTE Transcarotid NPS during carotid artery stenting (CAS) procedures
Number of subjects: 208
Study: 26506438

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV-13)
Number of subjects: 30
Study: 26507708

Group type: EXPERIMENTAL
Intervention: Amb a sublingual immunotherapy tablet
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Amb a extract
Number of subjects: 452
Study: 26507836

Group type: EXPERIMENTAL
Intervention: KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: KHK2866 (0.1 mg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: KHK2866 (all doses)
Number of subjects: 22
Study: 26507877

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 30
Study: 26508138

Group type: EXPERIMENTAL
Intervention: Tramadol (200-mg extended-release tablets)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: O-desmethyltramadol (ODM)
Number of subjects: 35
Study: 26508901

Group type: EXPERIMENTAL
Intervention: Chemotherapy without ifosfamide/etoposide
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Age, treatment, tumor location, and tumor size
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1444
Study: 26509071

Group type: EXPERIMENTAL
Intervention: Corticosteroids >5 mg/day
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Corticosteroids ≤5 mg/day
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Continued corticosteroid treatment
Number of subjects: 838
Study: 26509074

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 409
Study: 26509766

Group type: EXPERIMENTAL
Intervention: Microscope-integrated optical coherence tomography (MIOCT)
Number of subjects: 2
Study: 26510020

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice a day
Number of subjects: 50
Study: 26510696

Group type: EXPERIMENTAL
Intervention: Warfarin treatment (mean duration 1 year, mean INR 1.9 for IPAH, 2.0 for SSc-PAH)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Warfarin-naïve patients (matched control group)
Number of subjects: 374
Study: 26510775

Group type: EXPERIMENTAL
Intervention: PlayForward: Elm City Stories (videogame intervention)
Number of subjects: 166
Study: 26511221

Group type: EXPERIMENTAL
Intervention: Novel oral anticoagulants (NOACs) administered intermittently based on ICM guidance
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intermittent NOAC administration
Number of subjects: 59
Study: 26511224

Group type: EXPERIMENTAL
Intervention: Lacto-N-fucopentaose (LNFP) I
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Disialyl-lacto-N-tetraose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lacto-N-fucopentaose II (LNFPII)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fucosyl-disialyl-lacto-N-hexaose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose
Number of subjects: 25
Study: 26511652

Group type: EXPERIMENTAL
Intervention: Fluorinated (19F) agent CS-1000 labeled SVF cells
Number of subjects: 0
Study: 26511835

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (PM1 concentration at 314 μg/m(3) for 3 hours)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air exposure (control)
Number of subjects: 14
Study: 26511878

Group type: EXPERIMENTAL
Intervention: Pro-adrenomedullin (ProADM)
Number of subjects: 7132

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 7132

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 7132
Study: 26511896

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloons (DEBs)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both DEBs and BA
Number of subjects: 44
Study: 26511934

Group type: EXPERIMENTAL
Intervention: Blind repositioning techniques (withdrawn into the trachea and blindly readvanced without rotation, or with 90° or 180° counterclockwise rotation while the patient's head was turned right)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Smaller left-sided DLTs
Number of subjects: 1135
Study: 26512574

Group type: EXPERIMENTAL
Intervention: Gemcitabine, Vincristine, and Cisplatin (GVP) regimen
Number of subjects: 26
Study: 26512596

Group type: EXPERIMENTAL
Intervention: CMRLAX
Number of subjects: 100

Group type: COMPARATOR
Intervention: CMRSAX
Number of subjects: 100

Group type: COMPARATOR
Intervention: TTE
Number of subjects: 100
Study: 26512876

Group type: EXPERIMENTAL
Intervention: Continuous afatinib 30 mg plus nintedanib 150 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intermittent afatinib 40 mg plus nintedanib 150 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continuous afatinib plus nintedanib at MTD
Number of subjects: 70
Study: 26513619

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) imaging of the terminal ileum, with increased epithelial gap density observed in normal appearing mucosa.
Number of subjects: 24
Study: 26514176

Group type: EXPERIMENTAL
Intervention: (18)F-FIMX
Number of subjects: 12
Study: 26514251

Group type: EXPERIMENTAL
Intervention: RECO stent retriever
Number of subjects: 0
Study: 26514315

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg BID co-administered with digoxin 0.25 mg once daily on days 9 to 15
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin 0.25 mg BID on day 1 and 0.25 mg once daily on days 2 to 8
Number of subjects: 0
Study: 26514334

Group type: EXPERIMENTAL
Intervention: Splenic artery embolization (SAE)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall treatment (splenectomy and SAE)
Number of subjects: 109
Study: 26514420

Group type: EXPERIMENTAL
Intervention: Vaccine alone (10 μg dLPS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vaccine plus CPG 7909 (250 or 500 μg)
Number of subjects: 20
Study: 26514928

Group type: EXPERIMENTAL
Intervention: Behavioral support techniques (preparation, distraction, coaching, reinforcement) during in-office tympanostomy tube placement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Iontophoresis system for delivering local anesthesia and integrated tube delivery system
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Office-based local anesthesia and tube delivery with behavioral techniques
Number of subjects: 70
Study: 26515198

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (r-tPA) treatment
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Information presentation strategies for r-tPA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Risk-benefit communication regarding r-tPA
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Shared decision-making tool for r-tPA
Number of subjects: 106
Study: 26515246

Group type: EXPERIMENTAL
Intervention: Lower trunk accelerations during a six-minute walk test
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: One inertial sensor on the lower trunk
Number of subjects: 29
Study: 26515457

Group type: EXPERIMENTAL
Intervention: Once-daily Basal Insulin (BI) therapy in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily Basal Insulin (BI) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, duration of diabetes
Number of subjects: 0
Study: 26516010

Group type: EXPERIMENTAL
Intervention: APOC3 Loss-of-Function Mutations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no APOC3 mutations)
Number of subjects: 0
Study: 26516584

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg) as a single infusion or multiple intravenous infusions over 11 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime, avibactam, or ceftazidime-avibactam over 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000-500 mg), metronidazole (500 mg), or metronidazole followed by ceftazidime-avibactam over 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single and multiple doses of ceftazidime, avibactam, and metronidazole
Number of subjects: 0
Study: 26518132

Group type: EXPERIMENTAL
Intervention: 14-day treatment (T14) with chloroquine (CQ) for 3 days (10, 10, and 5 mg/kg) and primaquine (PQ) daily for 14 days (0.25 mg/kg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intermittent single dose (ISD) regimen with a single dose of CQ (10 mg/kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 14-day treatment (T14)
Number of subjects: 153
Study: 26518379

Group type: EXPERIMENTAL
Intervention: Collis-Nissen procedure
Number of subjects: 130

Group type: COMPARATOR
Intervention: Nissen procedure
Number of subjects: 130
Study: 26518736

Group type: EXPERIMENTAL
Intervention: Five-word test
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Combination of three neuropsychological tests (five-word, cognitive disorders examination, verbal fluency)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Cognitively healthy individuals (CHI)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Mild cognitive impairment or demented individuals (MCI-DI)
Number of subjects: 585
Study: 26518979

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy at an initial dose of 0.3 mg/kg/day for 2 weeks, followed by 0.6 mg/kg/day for an additional 2 weeks, then increased by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day until seizure free confirmed by HV-EEG.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy during the 12-week maintenance phase.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy.
Number of subjects: 20
Study: 26519231

Group type: EXPERIMENTAL
Intervention: Fostamatinib 150 mg
Number of subjects: 56
Study: 26520062

Group type: EXPERIMENTAL
Intervention: Shortness of Breath with Daily Activities (SOBDA) questionnaire
Number of subjects: 4967

Group type: COMPARATOR
Intervention: Responders (defined by TDI, SGRQ, CAT, and trough FEV1 levels)
Number of subjects: 4967
Study: 26521238

Group type: EXPERIMENTAL
Intervention: Geary Hinkley model for tumor volume measurement
Number of subjects: 0
Study: 26521268

Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV) and Sofosbuvir (SOF) for 12 weeks
Number of subjects: 34
Study: 26522260

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 26
Study: 26523388

Group type: EXPERIMENTAL
Intervention: Flood-illuminated adaptive optics (FIAO) imaging of the retinal periphery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shifting the entry pupil toward the optical axis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 50
Study: 26523525

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (obese women)
Number of subjects: 27
Study: 26525052

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at a dose of 0.2-1.4 μg/kg/h with symptom-triggered benzodiazepine (10 mg diazepam bolus) as needed
Number of subjects: 72

Group type: COMPARATOR
Intervention: Symptom-triggered 10 mg boluses of diazepam only
Number of subjects: 72
Study: 26525461

Group type: EXPERIMENTAL
Intervention: JASPER parent-mediated intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Psychoeducational intervention
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mirrored pacing strategy
Number of subjects: 86
Study: 26525557

Group type: EXPERIMENTAL
Intervention: Maternal HAART
Number of subjects: 3022

Group type: COMPARATOR
Intervention: HAART naïve mothers (CD4 < 250)
Number of subjects: 3022

Group type: COMPARATOR
Intervention: HAART ineligible mothers
Number of subjects: 3022
Study: 26526622

Group type: EXPERIMENTAL
Intervention: Acute-on-chronic disease (AoC)
Number of subjects: 103363

Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 103363

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 103363

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 103363

Group type: EXPERIMENTAL
Intervention: Elevated admission serum potassium
Number of subjects: 103363
Study: 26526721

Group type: EXPERIMENTAL
Intervention: CD133+ autologous stem cells administered intramuscularly
Number of subjects: 8
Study: 26526971

Group type: EXPERIMENTAL
Intervention: Lacosamide (up to 400 mg)
Number of subjects: 499
Study: 26526984

Group type: EXPERIMENTAL
Intervention: Galunisertib (80 mg, Cohort-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Galunisertib (150 mg, Cohort-2)
Number of subjects: 12
Study: 26527676

Group type: EXPERIMENTAL
Intervention: Clinician-reported response
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: 2014 NIH-calculated response
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Change in the 2005 NIH clinician-reported skin score
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Change in the 0 to 10 patient-reported itching score
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Change in the Lee skin symptom score
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Change in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant score
Number of subjects: 575
Study: 26527780

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning HSCT
Number of subjects: 114
Study: 26528500

Group type: EXPERIMENTAL
Intervention: Dual focus narrow band imaging (dNBI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 26
Study: 26528503

Group type: EXPERIMENTAL
Intervention: Guidewire biliary cannulation (GWC)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard contrast-assisted cannulation (CC)
Number of subjects: 320
Study: 26528879

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on 3rd postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) measured on 5th postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) and C-reactive protein (CRP) measured together on 5th postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measured on 3rd postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measured on 5th postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: White blood count (WBC) measured on 3rd postoperative day (POD)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: White blood count (WBC) measured on 5th postoperative day (POD)
Number of subjects: 504
Study: 26529118

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Escitalopram 30 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nortriptyline 100 mg
Number of subjects: 47
Study: 26529238

Group type: EXPERIMENTAL
Intervention: Two doses of AERAS-402 followed by MVA85A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Three doses of AERAS-402
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AERAS-402 followed by MVA85A
Number of subjects: 40
Study: 26529255

Group type: EXPERIMENTAL
Intervention: 24-hour fasting
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (sirtuin activator)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SIRT3 activation (genetic and pharmacologic)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (refed individuals)
Number of subjects: 19
Study: 26529370

Group type: EXPERIMENTAL
Intervention: Minimally invasive interval debulking surgery (MI-IDS)
Number of subjects: 52
Study: 26529569

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SYNTAX Score II
Number of subjects: 0